DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
S•••••• L••
Pharmaceuticalsgroup grade Bon a schedule nowsponsor unattributed
What matters now
- $4.85Mprincipal outstanding
$4.85M principal held by 1 lender; matures Dec 2026.
Q1 2026 · Refinancing is due in 3 months at a 100¢ mark.
FactBDC schedules of investments, 31 Mar 2026; a sum of the BDCs' pieces, a lower bound
Mark path, consensus per quarter end
100¢ · 99¢ · 100¢ · 99¢ · 100¢Q1 2025 to Q1 2026
Principal held
at least $4.8M
sum of BDC pieces, a lower bound
Fair value
$4.8M
100c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
0 equity pieces beside them
Next maturity
Dec 29, 2026
$4.8M inside 24 months
On the tape since
Sep 30, 2023
latest Mar 31, 2026
Events
1
dated, non-routine
Lender marks
each lender's own fair value over cost at Mar 31, 2026, folded to one row per lender
| Lender | Exposure | Current mark | QoQ change |
|---|---|---|---|
| S•••••••• P•••••• C••••• F••• L•• | $4.85M | 100¢ | +1 pts |
Every BDC piece · 1 position across 1 lenderlargest principal first, with instrument and rate
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| S•••••••• P•••••• C••••• F••• L•• | term loan first lien T••• L••• | N•••••••••, N••••••••• D••• Investments | F•••• L••• S••••• S•••••• | R••••••• | $4.8M | $4.8M 100c | SOFR+525 bp |
Capital structure as the BDCs see it
latest quarter end Mar 31, 2026
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien exited Mar 31, 2026 | at least $4.8M | 100c | SOFR+525 bp | Dec 29, 2026 | 1 |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Mar 31, 2026 | 1 | $4.8M | $4.8M | 100c | 0 |
| Dec 31, 2025 | 1 | $9.7M | $9.6M | 99c | 0 |
| Sep 30, 2025 | 1 | $4.9M | $4.8M | 100c | 0 |
| Jun 30, 2025 | 1 | $4.9M | $4.8M | 99c | 0 |
All 11 quartersShow fewer
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Mar 31, 2025 | 1 | $4.9M | $4.9M | 100c | 0 |
| Dec 31, 2024 | 1 | $19.7M | $19.4M | 99c | 0 |
| Sep 30, 2024 | 1 | $4.9M | $4.9M | 99c | 0 |
| Jun 30, 2024 | 1 | $4.9M | $4.9M | 100c | 0 |
| Mar 31, 2024 | 1 | $5.0M | $4.9M | 99c | 0 |
| Dec 31, 2023 | 1 | $5.0M | $4.9M | 99c | 0 |
| Sep 30, 2023 | 1 | $5.0M | $4.9M | 100c | 0 |
What changed
- Facility left every BDC scheduleMar 31, 2026
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- SEQUONderivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 1 BDCderived
- Industry
- Pharmaceuticalsreportedas one filer wrote it